General Information of This Drug (ID: DM3M652)

Drug Name
Daio-Orengedokuto (DOT)   DM3M652
Synonyms
26159-34-2; Miranax; Naproxen sodium salt; Synflex; Naprodol; Naprodil; Leniartril; Gibixen; Floxalin; Flogogin; Aprowell; Anapran; Primeral; Pactens; Naprovite; Gibinap; Floneks; Anaprotab; Monarit; Karoksen; Sodimax; Natrioxen; Floginex; Opraks; Kapnax; Tandax; Flogen; Nixal; Aprol; Naprux Gesic; Causalon Pro; Naproxen natrium; Axer Alfa; Dysmenalgit; Veradol; Naprium; Diocodal; Proxen; Prexan; Naprux; A-Nox; Xenar; Laser; Apo-Napro-NA; UNII-9TN87S3A3C; sodium na
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
Daio-Orengedokuto (DOT) + Idarubicin DCLY6NV Idarubicin Glioblastoma? (Cell Line: T98G) [2]
------------------------------------------------------------------------------------

References

1 Daio-Orengedokuto inhibits HMG-CoA reductase and pancreatic lipase. Biol Pharm Bull. 2002 Nov;25(11):1442-5.
2 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.